Baxter Bros Inc. Has $1.35 Million Stock Position in Pfizer Inc. $PFE

Baxter Bros Inc. trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE) by 6.6% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 55,588 shares of the biopharmaceutical company’s stock after selling 3,957 shares during the period. Baxter Bros Inc.’s holdings in Pfizer were worth $1,347,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of PFE. Bessemer Group Inc. raised its stake in shares of Pfizer by 11.1% during the 1st quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company’s stock worth $3,358,000 after purchasing an additional 13,228 shares in the last quarter. Capital Advisors Inc. OK raised its stake in shares of Pfizer by 1.2% during the 1st quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company’s stock worth $35,817,000 after purchasing an additional 17,032 shares in the last quarter. CHURCHILL MANAGEMENT Corp purchased a new stake in shares of Pfizer during the 1st quarter worth about $8,283,000. Westbourne Investments Inc. purchased a new stake in shares of Pfizer during the 1st quarter worth about $2,411,000. Finally, Bourne Lent Asset Management Inc. raised its stake in shares of Pfizer by 90.8% during the 2nd quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company’s stock worth $927,000 after purchasing an additional 18,200 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

PFE has been the topic of a number of analyst reports. Morgan Stanley increased their price objective on Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a report on Wednesday, August 6th. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a report on Wednesday. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Citigroup increased their price objective on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Finally, UBS Group reissued a “neutral” rating and set a $28.00 price objective on shares of Pfizer in a report on Wednesday, October 1st. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $28.41.

Pfizer Price Performance

Shares of NYSE:PFE opened at $25.67 on Thursday. The business has a 50 day moving average price of $24.79 and a 200 day moving average price of $24.15. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $30.43. The company has a market cap of $145.95 billion, a price-to-earnings ratio of 13.65, a PEG ratio of 0.86 and a beta of 0.55. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter in the prior year, the company earned $0.60 EPS. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.